Expression of NALP3 in the spleen of mice with portal hypertension

Abstract

This study examined the mRNA expression of NALP3 in the spleen of the mice with hypersplenism due to portal hypertension (PH). The mouse hypersplenism models were established by oral administration of tetrachloromethane (2 mL/kg/week for 12 weeks by oral gavage). All the mice were randomly divided into a control group and an experimental group. The blood routine test was conducted, spleen index was calculated and spleen was histologically examined. Portal vein sera were taken for detection of the level of uric acid. The mRNA expressions of NALP3 and IL-1β in the spleen were detected by reverse transcriptase-polymerase chain reaction (RT-PCR). The results showed that the platelet count was significantly lower in the experimental group [(674±102)×10⁹/L] than in the control group [(1307±181)×10⁹/L] (P<0.05), while the spleen index was significantly higher [(9.83±1.36) μg/g] in the experimental group than in the control group [(4.11±0.47) μg/g] (P<0.05). The histopathological changes of spleen followed the pattern of congestive splenomegaly. No significant difference was found in the uric acid level in the portal vein between the control group and the experiment group. The mRNA expressions of NALP3 and IL-1β were up-regulated significantly in the spleen in the experimental group as compared with those in the control group (P<0.05). It was concluded that NALP3 and IL-1β may play important roles in the pathogenesis of hypersplenism.

Keywords

NALP3 / interleukin-1β / hypersplenism / hypertension, portal

References

[1] LvY.F.. Characteristics and clinical significance of hypersplenism secondary to splenomegaly caused by cirrhotic portal hypertension. World Chin J Digestol (Chinese), 2009, 17(29): 2969-2971

[2] LiZ.F., ZhangS.. The progress and prospect of fundamental research of the spleen. J Xi’an Jiaotong Univ (Med Sci) (Chinese), 2008, 29(1): 1-6

[3] Peck-RadosavljevicM.. Hypersplenism. Eur J Gastroenterol Hepatol, 2001, 13(4): 317-323

[4] McCormickP.A., MurphyK.M.. Splenomegaly, hypersplenism and coagulation abnormalities in liver disease. Baillieres Best Pract Res Cli Gastroenterol, 2000, 14(6): 1009-1031

[5] AllerM.A., VaraE., GarciaC., et al.. Proinflammatory liver and anti-inflammatory intestinal mediators involved in portal hypertensive rats. Mediators Inflamm, 2005, 2005(2): 101-111

[6] PalmaM.D., AllerM.A., VaraE., et al.. Portal hypertension produces an evolutive hepato-intestinal pro- and anti-inflammatory response in the rats. Cytokine, 2005, 31(3): 213-226

[7] AgostiniL., MartinonF., BurnsK., et al.. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity, 2004, 20(3): 243-244

[8] ReinaE.M., GeorgK.. Structure and function of the spleen. Nat Rev Immunol, 2005, 5(8): 606-616

[9] MedzhitovR.. Origin and Physiological roles of inflammation. Nature, 2008, 454(7203): 428-535

[10] Sánchez-PatánF., AnchueloR., AllerM.A., et al.. Chronic prehepatic portal hypertension in the rat: is it a type of metabolic inflammatory syndrome?. Lipids Health Dis, 2008, 7: 4

[11] ChurchL.D., CookG.P., McDermottM.F.. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol, 2008, 4(1): 34-42

[12] LuheshiN.M., RothwellN.J., BroughD.. Dual functionality of interleukin-1 family cytokines: implications for anti-interleukin-1 therapy. Br J Pharmacol, 2009, 157(8): 1318-1329

[13] PapadakiH.A., CharoulakisN.Z., EliopoulosD.G., et al.. Patients with non-immune chronic idiopathic neutropenia syndrome have increased splenic volume on ultrasonography. Clin Lab Haematol, 2001, 23(2): 111-117

[14] SchmitzG., KaminskiW.E., Porsch-OzcurumezM., et al.. ATP-binding cassette transporter A1 (ABCA1) in macrophages: a dual function in inflammation and lipid metabolism?. Pathobiology, 1999, 67(5–6): 236-240

[15] AnnettH., VeitH., GaborC.P., et al.. The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat Immunol, 2008, 9(8): 857-865

[16] TschoppJ., MartinonF., BurnsK.. NALPs: a novel protein family involved in inflammation. Nat Rev Mol Cell Biol, 2003, 4(2): 95-104

[17] MartinonF., GaideO., PetrilliV., et al.. NALP inflammasomes: a central role in innate immunity. Semin Immunopathol, 2007, 29(3): 213-229

[18] MeylanE., TschoppJ., KarinM.. Intracellular pattern recognition receptors in the host response. Nature, 2006, 442(7098): 39-44

[19] OguraY., SutterwalaF.S., FlavellR.A.. The Inflammasome: First line of the immune response to cell stress. Cell, 2006, 126(4): 659-662

[20] LamkanfiM., DixitV.M.. Inflammasomes: guardians of cytosolic sanctity. Immunol Rev, 2009, 227(1): 95-105

[21] MartinonF., TschoppJ.. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ, 2007, 14(1): 10-22

[22] BryantC., FitzgeraldK.A.. Molecular mechanisms involved in inflammasome activation. Trends Cell Biol, 2009, 19(9): 455-464

[23] MartinonF., PetrilliV., MayorA., et al.. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature, 2006, 440(7081): 237-241

[24] Liu-BryanR.. Intracellular innate immunity in gouty arthritis: role of NALP3 inflammasome. Immunol Cell Biol, 2010, 88(1): 20-23

[25] GotschF., RomeroR., ChaiworapongsaT., et al.. Evidence of the involvement of caspase-1 under physiologic and pathologic cellular stress during human pregnancy: A link between the inflammasome and parturition. J Matern Fetal Neonatal Med, 2008, 21(9): 605-616